Physician profile

Stephen C Hall

Plastic and Reconstructive Surgery · Summit, NJ

NPI 1639237241

$552.26

in general payments reported to CMS, 2019-2025

9 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$372.96

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Astrazeneca Pharmaceuticals LP $143.32 2022-2023 Enhertu
Merck Sharp & Dohme LLC $132.45 2022-2024 Keytruda
Hologic INC $93.48 2024 Localizer
Lilly USA, LLC $54.88 2019-2020
Bayer Healthcare Pharmaceuticals INC. $39.64 2022-2023
Roche Diagnostics Corporation $39.29 2019
Daiichi Sankyo INC. $17.00 2023 Injectafer
Eisai INC. $16.91 2022
Janssen Biotech, INC. $15.29 2022

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Stephen C Hall

$552.26

in general payments reported 2019-2025

Years
2019-2024
Top company
Astrazeneca Pharmaceuticals LP

https://glasscript.com/doctor/1064484/stephen-c-hall

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.